TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04698330
Drug: Inulin
Normalized name: Inulin
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months
Study: NCT04698330
Drug: Berberine placebo tablets
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months
Study: NCT04698330
Drug: Inulin placebo tablets
Normalized name: placebo Oral Tablet
DrugBank: Inulin (DB00638)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months
Study: NCT05246111
Drug: [14C]Berzosertib
DrugBank: Berzosertib (DB11794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single intravenous infusion of \[14C\]Berzosertib at a dose of 210 milligrams per square meter (mg/m\^2) on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
Study: NCT04664738
Drug: TISSEEL
Normalized name: Tisseel
DrugBank: Calcium chloride (DB01164)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fibrin sealant made from pooled human plasma
Study: NCT04863430
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500mg oral qd
Study: NCT04863430
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130mg/m\^2 administered as IV infusion on Days 1 of each 21-day cycle
Study: NCT05246111
Drug: Berzosertib
Normalized name: Berzosertib
DrugBank: Berzosertib (DB11794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received single intravenous infusion of Berzosertib at a dose of 210 mg/m\^2 on Day 2 and Day 5 in period 2 until disease progression or other criteria for study intervention discontinuation were met.
Study: NCT05246111
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation were met.
Study: NCT05317000
Drug: Combination 5-azacytidine and nivolumab
DrugBank: Cytidine (DB02097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The primary objective of the study is to determine whether exposure to the demethylating agent 5-azacytidine will sensitize HPV-associated oropharynx cancer to nivolumab by induction of interferon response, neoantigen expression, and augmentation of lymphocyte infiltration of the tumor microenvironment.
Study: NCT05317000
Drug: 5-azacytidine
Normalized name: 5-azacytidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Chemotherapy is the use of drugs to destroy cancer cells. It usually works by keeping the cancer cells from growing, dividing, and making more cells. Because cancer cells usually grow and divide faster than normal cells, chemotherapy has more of an effect on cancer cells. 5-azacytidine works by slowing down the growth of cancer cells. 5-azacytidine has been demonstrated to improve the cell's ability to make some proteins which signal to the immune system.
Study: NCT04863430
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to body surface area,(\<1.5m\^2) 40mg or (≥1.5m\^2)50mg bid oral on Day 1-14 of each 21-day cycle
Study: NCT03952299
Drug: Oxybutynin Transdermal Patch
Normalized name: oxybutynin Transdermal Product
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal patch of oxybutynin will be used instead of oral oxybutynin.
Study: NCT03952299
Drug: Oral Oxybutynin
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of oxybutynin (5mg) every 8 hours in the hospital.
Study: NCT05317000
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Immunotherapy is a type of treatment that uses your body's own immune system to help fight cancer. Specifically, Nivolumab belongs to a class of anti-cancer drugs known as immune checkpoint inhibitors. Cancer cells are able to turn off the immune system by increasing the production of a protein called PD-1. Nivolumab can block PD-1 and may be able to re-activate the immune response to kill head and neck cancer cells.
Study: NCT05576597
Drug: Sodium Butyrate
Normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 capsules butyrate supplement once a day for 12 weeks
Study: NCT06385145
Drug: PEG-rhGH with new preparation (T)
Normalized name: RhGH-PEG
DrugBank: Lonapegsomatropin (DB16220)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single subcutaneous injection of PEG-rhGH with new preparation
Study: NCT06385145
Drug: PEG-rhGH with present preparation (R)
Normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single subcutaneous injection of PEG-rhGH with present preparation
Study: NCT00002167
Drug: Tin ethyl etiopurpurin
Normalized name: Tin ethyl etiopurpurin
DrugBank: Rostaporfin (DB06659)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05264714
Drug: Rimegepant
Normalized name: RIMEGEPANT
DrugBank: Rimegepant (DB12457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg oral disintegrating tablet every other day for one week
Study: NCT05655806
Drug: Aminophylline bolus then infusion
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: half an hour before discontinuation of isoflurane
Study: NCT05655806
Drug: aminophylline bolus
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: after discontinuation of isoflurane
Study: NCT06209203
Drug: lowe-dose ZKY001 eye drops
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: eye drops
Study: NCT06209203
Drug: Medium-dose ZKY001 eye drops
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: eye drops
Study: NCT06133517
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan is administered at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle.
Study: NCT06133517
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZIM is administered at 360 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
Study: NCT06133517
Drug: Domvanalimab
Normalized name: Domvanalimab
DrugBank: Domvanalimab (DB18848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOM is administered at 1200 mg every 3 weeks as an intravenous (IV) infusion on Day 1 of a 21-day cycle.
Study: NCT05776056
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate 10mg will be taken twice daily.
Study: NCT06475742
Drug: Cenerimod
Normalized name: Cenerimod
DrugBank: Cenerimod (DB12705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablets at a dose of 4 mg.
Study: NCT04936035
Drug: ALN-AGT01
Normalized name: ALN-AT3SC
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN-AGT01 administered by SC injection
Study: NCT06214793
Drug: Taletrectinib
Normalized name: taletrectinib
DrugBank: taletrectinib (DB18711)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taletrectinib (AB-106/DS-6051b) is a potent, highly selective, orally bioavailable ROS1 and TRK family inhibitor, which has activity against mutations conferring resistance to crizotinib including in vitro and in vivo against the acquired ROS1 G2032R solvent front mutation. Taletrectinib has been shown to have anti-tumor activity against recombinant ROS1, NTRK1, and NTRK3 in sub-nanomolar concentration in an ATP dependent manner, in addition to completely inhibiting ACK, ALK, DDR1 and LTK at micromolar concentrations. Anti-tumor activity of taletrectinib was observed in two ROS1 rearranged lung cancer cell lines, glioblastoma cell line, and in NTRK-rearranged colorectal cancer cell lines.
Study: NCT05102591
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention in 50 mL mini bag of normal saline (0.9% NaCl) for target dose of 0.15 mg/kg, maximum 10 mg of metoclopramide (2 mL), and administer as infusion over 15-30 minutes
Study: NCT05524883
Drug: DYNE-251
Normalized name: DYNE-251
DrugBank: DYNE-251 (DB18130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by IV infusion
Study: NCT05596955
Drug: Buprenorphine injection
Normalized name: buprenorphine Injection
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Extended release once-a-month buprenorphine injection . Study arm undergoes 2 fMRI examinations and weekly monitoring visits
Study: NCT05596955
Drug: Naltrexone Injection
Normalized name: naltrexone Injection
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release once-a-month naltrexone injection. Study arm undergoes 2 fMRI examinations and weekly monitoring visits
Study: NCT05328167
Drug: Perflutren Protein-Type A Microspheres
Normalized name: perflutren protein-type A microspheres
DrugBank: Perflutren (DB00556)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT06588413
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to either olanzapine 2.5 mg or 5 mg
Study: NCT06197776
Drug: cisplatin-based chemoradiotherapy combined with immunotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy:cisplatin-based chemotherapy~GP/TP/PF/TPF~Choice of chemotherapy regimen is decided by patient's doctor in charge.~Radiation: Intensity Modulated Radiation Therapy~All target volumes will be outlined slice by slice on the axial contrast-enhanced CT with MR fusion images in the treatment planning system. The target volumes are defined in accordance with the International Commission on Radiation Units and Measurements Reports 83. The prescribed dose is 70-72 Gy to PTVp (Planning target volume of the primary tumor), 64-70 Gy to PTVn (Planning target volume of the lymph node),60- 64Gy to PTV1 (High-risk planning target volume), and 54-58 Gy to PTV2 (Low-risk planning target volume) in 30-32 fractions. The details of dose limits for organs at risk are based on the study 0225 from The Radiation Therapy Oncology Group (RTOG 0225).~Immunotherapy:PD-1 blocking antibody
Study: NCT04949256
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg QD (induction) or 20 mg QD (consolidation) via oral capsule.
Study: NCT04949256
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 75 mg/m\^2 Q3W via infusion, as part of investigator's choice TP chemotherapy.
Study: NCT04949256
Drug: 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4000 mg/m\^2 Q3W via IV infusion, as part of investigator's choice FP chemotherapy or 400 mg/m\^2 Q2W via bolus IV infusion followed by 2400 mg/m\^2 Q2W via continuous IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
Study: NCT04754425
Drug: Erdafitinib
Normalized name: erdafitinib
DrugBank: Erdafitinib (DB12147)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT04949256
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85 mg/m\^2 Q2W via IV infusion, as part of investigator's choice mFOLFOX6 chemotherapy.
Study: NCT04949256
Drug: Levoleucovorin
Normalized name: Levoleucovorin
DrugBank: Levoleucovorin (DB11596)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m\^2 Q2W as part of investigator's choice mFOLFOX6 chemotherapy.
Study: NCT04949256
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m\^2 Q3W via IV infusion, as part of investigator's choice TP chemotherapy.
Study: NCT04774068
Drug: Parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04774068
Drug: Romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT05652322
Drug: Furosemide Pill 150% equivalent iv dose
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: change from intravenous to oral furosemide
Study: NCT05652322
Drug: Furosemide Pill 200% equivalent iv dose
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: change from intravenous to oral furosemide
Study: NCT05652322
Drug: Furosemide Injection
Normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: change from intravenous to oral furosemide
Study: NCT06327646
Drug: Multiple Micronutrient Supplement Bottle
Normalized name: bottlebrush pollen extract
DrugBank: Callistemon citrinus pollen (DB10943)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMS in bottles along with related job aids, counselling during ANC, etc.
Study: NCT05601154
Drug: Crest Cavity Protection toothpaste
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will brush their teeth with Crest Cavity Protection toothpaste (1,100 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
Study: NCT06242834
Drug: Tazemetostat
Normalized name: tazemetostat
DrugBank: Tazemetostat (DB12887)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT05601154
Drug: Colgate PreviDent 5000+ toothpaste
Normalized name: potassium nitrate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of tap water for 10 seconds
Study: NCT05601154
Drug: Colgate PreviDent 5000+ toothpaste followed by Act Mint Fluoride Rinse
Normalized name: potassium nitrate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will brush their teeth with Colgate PreviDent 5000+ (5,000 ppm F) for 1 minute, expectorate the foam, and rinse their mouths with 10 mL of Act Mint Fluoride Rinse (226 ppm) for 1 minute
Study: NCT06317350
Drug: GNS-212-ER
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects who are randomized into this group will take active control drug (PEG3350) from the evening before colonoscopy to the morning of colonoscopy.
Study: NCT05117957
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive sorafenib 600mg orally daily. When dose reduction is necessary during the treatment of HCC, the sorafenib dose should be reduced to 400mg once daily. Escalation of sorafenib from a daily dose of 600mg to 800mg (400mg twice daily) is allowed if the subject who is tolerating the 600mg sorafenib dose level well. Treatment will continue until progression, unacceptable toxicity, withdrawal of consent, or study end, whichever occurs first.
Study: NCT04901702
Drug: Onivyde
Normalized name: Onivyde
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given intravenous on Days 1 and 8
Study: NCT04901702
Drug: Talazoparib
Normalized name: TALAZOPARIB
DrugBank: Talazoparib (DB11760)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally twice on Day 1 (daily maximum is 1000mcg/day), then daily on Days 2-6
Study: NCT04901702
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given once a day on Days 1-5.
Study: NCT04617522
Drug: Sacituzumab Govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT05148702
Drug: Antibiotic - fixed-extended-duration
Normalized name: oxymetazoline hydrochloride Nasal Spray [Duration]
DrugBank: Oxymetazoline (DB00935)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clinician decided antibiotic for a fixed duration of 28 days.
Study: NCT04551521
Drug: Vemurafenib
Normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 960 mg twice daily during run-in Phase, followed by 720 mg twice daily
Study: NCT04551521
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 60 mg once daily
Study: NCT04551521
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 840 mg every 2 weeks
Study: NCT04551521
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 mg per kilogram of body weight as a loading dose, followed by 6 mg per kilogram every 3 weeks
Study: NCT04551521
Drug: Pertuzumab
Normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 840 mg as a loading dose, followed by 420 mg intravenously every 3 weeks
Study: NCT06703879
Drug: Anesthesia induction with propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Establishment of a database of clinical characteristics of propofol-induced loss of consciousness in patients with complete clinical information Acquisition of basic perioperative monitoring data and extended monitoring data: 1,000 patients aged ≥18 years who needed to undergo surgical treatment were included (according to the machine learning diagnosis results, if the poor model fit was due to the small sample size, the necessary number of samples could be continued to be collected), and perioperative monitoring and management of the patients was performed, and a video recorder was used to videotape the whole anesthesia induction process in real time, so as to facilitate the postoperative integration of various data. The basic characteristics of the patients and the perioperative monitoring characteristics were extracted from the surgical anesthesia recording system, including gender, age, height, weight, blood pressure, ASA classification, electroencephalographic parameters, the a
Study: NCT04551521
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 600 mg twice daily
Study: NCT04551521
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg once daily
Study: NCT04551521
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg every 3 weeks
Study: NCT04551521
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1200 mg in the first cycle, followed by 840 mg every 3 weeks
Study: NCT04551521
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1,200 mg every 3 weeks
Study: NCT04551521
Drug: Inavolisib
Normalized name: Inavolisib
DrugBank: Inavolisib (DB15275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 mg once daily
Study: NCT05473234
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Children enrolled in the trial and randomized to receive amoxicillin will receive a 5-day course of amoxicillin to be given in twice-daily doses of 15 mg/kg per the Nigeria guidelines for severe acute malnutrition. The first dose will be administered at the time of enrollment, and the remaining doses will be administered by the caregiver at home. Enrolled children will also receive RUTF.
Study: NCT05890768
Drug: Lumateperone
Normalized name: Lumateperone
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FDA approved antipsychotic drug
Study: NCT05527834
Drug: Ceftibuten
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose
Study: NCT05890768
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: FDA approved antipsychotic drug
Study: NCT06524687
Drug: Imvotamab
Normalized name: Imvotamab
DrugBank: Imvotamab (DB17331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04485039
Drug: Tecovirimat
Normalized name: Tecovirimat
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral antiviral
Study: NCT04485039
Drug: sevelamer carbonate oral tablet
Normalized name: sevelamer carbonate Oral Tablet
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phosphate binder
Study: NCT04485039
Drug: sucroferric oxyhydroxide chewable tablet
Normalized name: sucroferric oxyhydroxide Chewable Tablet
DrugBank: Ferric sulfate (DB11171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phosphate binder
Study: NCT04485039
Drug: Lanthanum Carbonate Chewable Tablet
Normalized name: lanthanum carbonate Chewable Tablet
DrugBank: Lanthanum carbonate (DB06792)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: phosphate binder
Study: NCT04918186
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500mg IV, 60 min day 1 every 4 weeks
Study: NCT04918186
Drug: ENB003
Normalized name: ENB003
DrugBank: ENB-003 (DB17340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT04918186
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV
Study: NCT04785196
Drug: APG-115
Normalized name: APGA
DrugBank: Aminopterin (DB08878)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation of APG-115 in combination with label dose of toripalimab, four dose levels of APG-115 will be tested: 50, 100, 150, and 200mg. APG-115 will be administrated orally every other day (QOD) for consecutive 2 weeks (ie. dosed at Day 1, 3, 5, 7, 9, 11, and 13), with one week dosing off as 3 weeks a cycle.
Study: NCT04785196
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab is administrated following CDE approved label dose, i.e.: 240 mg intravenous infusion at Day 1 of every 3 weeks as a cycle.